2-methyl-2-pyridin-4-ylpropionic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-methyl-2-pyridin-4-ylpropionic acid
• 英文别名: α,α-Dimethyl-4-Pyridyl Acetic Acid；2-Methyl-2-(pyridin-4-yl)propanoic acid；2-methyl-2-pyridin-4-ylpropanoic acid
• 化学式: C₉H₁₁NO₂
• 分子量: 165.192
• InChiKey: NXMDCBMOHHILDN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  50.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-methyl-2-pyridin-4-ylpropionic acid 在 盐酸 、 platinum(IV) oxide hydrate 、 水 、 氢气 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 37.17h， 生成 4-[1-(5-cyclohexyl-4H-[1,2,4]triazol-3-yl)-1-methylethyl]piperidine
  参考文献：
  名称：

  [EN] N1-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE
  [FR] DÉRIVÉS DE N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-MÉTHYLPROPIONYL)-PIPÉRIDINE EN TANT QU'INHIBITEURS DE LA PYRUVATE DÉSHYDROGÉNASE KINASE

  摘要：

  式(I)中的化合物，其中X、Q、R1和R2具有权利要求1中指示的含义，是丙酮酸脱氢酶激酶（PDHK）的抑制剂，可用于治疗癌症等疾病。

  公开号：

  WO2017167676A1
• 作为产物：
  描述：

  2-methyl-2-pyridin-4-ylpropionic acid ethyl ester 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 20.0h， 以85%的产率得到2-methyl-2-pyridin-4-ylpropionic acid
  参考文献：
  名称：

  [EN] N1-(3,3,3-TRIFLUORO-2-HYDROXY-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE
  [FR] DÉRIVÉS DE N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-MÉTHYLPROPIONYL)-PIPÉRIDINE EN TANT QU'INHIBITEURS DE LA PYRUVATE DÉSHYDROGÉNASE KINASE

  摘要：

  式(I)中的化合物，其中X、Q、R1和R2具有权利要求1中指示的含义，是丙酮酸脱氢酶激酶（PDHK）的抑制剂，可用于治疗癌症等疾病。

  公开号：

  WO2017167676A1

文献信息

• [EN] ORGANIC COMPOUNDS<br/>[FR] COMPOSES ORGANIQUES
  申请人：SPEEDEL EXPERIMENTA AG

  公开号：WO2005090304A1

  公开（公告）日：2005-09-29

  The invention relates to novel amino alcohols of the general formula (I) where X, R1, R2, R3, R4, R5 and R6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  这项发明涉及一般式(I)的新型氨基醇，其中X、R1、R2、R3、R4、R5和R6的定义详细描述在说明书中，以及它们的制备方法和将这些化合物用作药物，特别是作为肾素抑制剂。
• Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
  申请人：——

  公开号：US20030055065A1

  公开（公告）日：2003-03-20

  A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: 1 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of the formulas 2 are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

  本发明揭示了一种抑制Ras功能，从而抑制细胞异常生长的方法。该方法包括向生物系统中给予1.0:1式化合物。特别是，该方法抑制哺乳动物（如人类）中细胞的异常生长。本发明还揭示了新的2式化合物。还揭示了制备5.0、5.1、5.2和5.3式3-取代化合物的方法。本发明还揭示了制备3-取代化合物5.0、5.1、5.2和5.3式的中间体。
• Organic Compounds
  申请人：Herold Peter

  公开号：US20080058320A1

  公开（公告）日：2008-03-06

  The invention relates to novel amino alcohols of the general formula (I) where X, R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are each as defined in detail in the description, to a process for their preparation and to the use of these compounds as medicines, in particular as renin inhibitors.

  本发明涉及一种新型的氨基醇，其通式为(I)，其中X，R1，R2，R3，R4，R5和R6分别如详细描述中所定义，以及其制备方法和这些化合物作为药物的用途，特别是作为肾素抑制剂。
• Piperidinyl-propanone derivatives
  申请人：Merck Patent GmbH

  公开号：US11026936B2

  公开（公告）日：2021-06-08

  Compounds of the formula I in which X, Q, R1 and R2 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

  式 I 的化合物 是丙酮酸脱氢酶激酶（PDHK）的抑制剂，可用于治疗癌症等疾病。
• Inhibitors of Farnesyl Protein Transferase. 4-Amido, 4-Carbamoyl, and 4-Carboxamido Derivatives of 1-(8-Chloro-6,11-dihydro-5<i>H</i>-benzo[5,6]- cyclohepta[1,2-<i>b</i>]pyridin-11-yl)piperazine and 1-(3-Bromo-8-chloro-6,11- dihydro-5<i>H</i>-benzo[5,6]cyclohepta[1,2-<i>b</i>]pyridin-11-yl)piperazine
  作者：Alan K. Mallams、Randall R. Rossman、Ronald J. Doll、Viyyoor M. Girijavallabhan、Ashit K. Ganguly、Joanne Petrin、Lynn Wang、Robert Patton、W. Robert Bishop、Donna M. Carr、Paul Kirschmeier、Joseph J. Catino、Matthew S. Bryant、Kwang-Jong Chen、Walter A. Korfmacher、Cymbelene Nardo、Shiyong Wang、Amin A. Nomeir、Chin-Chung Lin、Zujun Li、Jianping Chen、Suining Lee、Janet Dell、Philip Lipari、Michael Malkowski、Bodan Yaremko、Ivan King、Ming Liu

  DOI：10.1021/jm970462w

  日期：1998.3.1

  The synthesis of a variety of novel 4-amido, 4-carbamoyl and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin -11-yl)piperazine to explore the SAR of of this series of FPT inhibitors is described. This resulted in the synthesis of the 4- and 3-pyridylacetyl analogues 45a and 50a, respectively, both of which were orally active but were found to be rapidly metabolized in vivo. Identification of the principal metabolites led to the synthesis of a variety of new compounds that would be less readily metabolized, the most interesting of which were the 3- and 4-pyridylacetyl N-oxides 80a and 83a. Novel replacements for the pyridylacetyl moiety were also sought, and this resulted in the discovery of the 4-N-methyl and 4-N-carboxamidopiperidinylacetyl derivatives 135a and 160a, respectively. All of these derivatives exhibited greatly improved pharmacokinetics. The synthesis of the corresponding 3-bromo analogues resulted in the discovery of the 4-pyridylacetyl N-oxides 83b (+/-) and 85b [11S(-)] and the 4-carboxamidopiperidinylacetamido derivative 160b (+/-), all of which exhibited potent FPT inhibition in vitro. All three showed excellent oral bioavailability in vivo in nude mice and cynomolgus monkeys and exhibited excellent antitumor efficacy against a series of tumor cell lines when dosed orally in nude mice.